Want to see AU:ANR full AI Analyst Report?
ANR Stock Chart & Stats
AU$0.01
<AU$0.01(3.85%)
At close: 4:00 PM EST
AU$0.01
<AU$0.01(3.85%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume35.84K
Average Volume (3M)759.89K
Market Cap
AU$3.16M
Enterprise ValueAU$1.20M
Total Cash (Recent Filing)AU$1.09M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding315,950,780
10 Day Avg. Volume1,527,300
30 Day Avg. Volume759,886
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.91
Price to Sales (P/S)1.06
P/FCF Ratio-0.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Pipeline (GaRP)A focused lead program (GaRP) targeting gastrointestinal health gives the company a clear development path. Ongoing clinical/validation and regulatory work indicate methodical progression toward market entry, which supports durable value creation if trials and approvals advance.
Revenue ReboundA strong year-over-year revenue rebound signals early commercial traction or milestone income, demonstrating the business can generate top-line growth. If maintained and scaled, this underpins longer-term ability to improve margins and reduce dependency on external funding.
Partnering/commercialisation PlanningActive partnering and commercialization planning is a durable strategic lever: it can accelerate market access, leverage partner distribution and reduce the firm's capital burden. Successful partnerships can materially de-risk late-stage commercialization and scale-up.
Bears Say
Negative Gross Profit And MarginsPersistently negative gross profit and deeply negative net margins show core costs exceed revenue, indicating the current business model is not yet economically sustainable. Without structural margin improvement, losses will continue to erode equity and limit strategic options.
High Cash Burn And Weak Cash GenerationConsistent negative operating and free cash flow, with increasing burn, creates an enduring reliance on external capital. That pressures management to raise funds (dilution risk), constrains trial spending or commercialization timing, and limits runway for executing strategy.
Deteriorating Balance Sheet / Declining EquitySharply reduced equity and rising leverage materially weaken financial flexibility. A thin capital base limits the company's ability to fund clinical programs, negotiate favorable partner terms, or withstand setbacks, increasing long-term execution and solvency risk.
Anatara Lifesciences Ltd News
ANR FAQ
What was Anatara Lifesciences Ltd’s price range in the past 12 months?
Anatara Lifesciences Ltd lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Anatara Lifesciences Ltd’s market cap?
Anatara Lifesciences Ltd’s market cap is AU$3.16M.
When is Anatara Lifesciences Ltd’s upcoming earnings report date?
Anatara Lifesciences Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 52 days.
How were Anatara Lifesciences Ltd’s earnings last quarter?
Anatara Lifesciences Ltd released its earnings results on Feb 25, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Anatara Lifesciences Ltd overvalued?
According to Wall Street analysts Anatara Lifesciences Ltd’s price is currently Overvalued.
Does Anatara Lifesciences Ltd pay dividends?
Anatara Lifesciences Ltd does not currently pay dividends.
What is Anatara Lifesciences Ltd’s EPS estimate?
Anatara Lifesciences Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anatara Lifesciences Ltd have?
Anatara Lifesciences Ltd has 315,950,780 shares outstanding.
What happened to Anatara Lifesciences Ltd’s price movement after its last earnings report?
Anatara Lifesciences Ltd reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Anatara Lifesciences Ltd?
Currently, no hedge funds are holding shares in AU:ANR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anatara Lifesciences Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-79.31%
12-Months-Change
Fundamentals
Return on Equity
-109.45%
Trailing 12-Months
Asset Growth
-24.67%
Trailing 12-Months
Company Description
Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Technical Analysis
AnteoTech Ltd
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---